CLUSTREL Project develops an advanced bioelectronic drug-delivery platform that addresses the critical need for rapid intervention in epilepsy, where seizures are caused by abnormal, excessive neuronal firing. The innovation pioneers the use of graphene-based materials for the electrically triggered release of anti-seizure medication. It combines nanotechnology, microelectronics, and biocompatible polymers to create an electro-responsive system capable of storing and releasing bioactive molecules on demand. CLUSTREL Project advances the technology toward clinical readiness by shifting from invasive, direct brain-contact applications to a non-invasive, organism-level device using transmucosal delivery routes.
The integrated model is built upon:
Graphene-based materials for electrically triggered drug release
A shift to non-invasive transmucosal delivery routes
Integration of material science, controlled drug release, and closed-loop neuromodulation principles
Future Needs primary role focuses on strategic exploitation, business strategy, and communication.
Key responsibilities and activities for Future Needs include:
Communication & Visibility – Leading tasks to implement a detailed communication strategy, manage the project's visual identity, and maintain the dedicated website.
Stakeholder Alignment – Leading tasks to ensure market alignment by establishing a Stakeholders Forum involving patients, neurologists, regulators, and industry partners.
Exploitation & Business Planning – Focusing on developing the CLUSTREL’s solution business plan and ensure market uptake
CLUSTREL combines nanotechnology, microelectronics, and material science to offer a safer, precise, and patient-friendly treatment option for epilepsy and potentially other neurological disorders. The project’s efforts:
